NASDAQ:BMRN BioMarin Pharmaceutical Q3 2026 Earnings Report $60.04 +0.17 (+0.28%) Closing price 03:59 PM EasternExtended Trading$60.43 +0.39 (+0.65%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BioMarin Pharmaceutical EPS ResultsActual EPSN/AConsensus EPS $1.34Beat/MissN/AOne Year Ago EPSN/ABioMarin Pharmaceutical Revenue ResultsActual RevenueN/AExpected Revenue$1.02 billionBeat/MissN/AYoY Revenue GrowthN/ABioMarin Pharmaceutical Announcement DetailsQuarterQ3 2026Date10/26/2026TimeAfter Market ClosesConference Call DateMonday, October 26, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile BioMarin Pharmaceutical Earnings HeadlinesBioMarin Grants Ascendis Global License, Secures Royalty Revenues3 hours ago | tipranks.comComparing BioMarin Pharmaceutical (NASDAQ:BMRN) and Ionis Pharmaceuticals (NASDAQ:IONS)September 28 at 3:58 AM | americanbankingnews.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 30 at 1:00 AM | TradeSmith (Ad)Oramed Pharmaceuticals (NASDAQ:ORMP) versus BioMarin Pharmaceutical (NASDAQ:BMRN) Critical SurveySeptember 23, 2026 | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Tilray (TLRY) and BioMarin Pharmaceutical (BMRN)September 22, 2026 | theglobeandmail.comBioMarin: Why I See Significant Upside Into 2027September 21, 2026 | seekingalpha.comSee More BioMarin Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioMarin Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioMarin Pharmaceutical and other key companies, straight to your email. Email Address About BioMarin PharmaceuticalBioMarin Pharmaceutical (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy. Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates. BioMarin has also developed Roctavian, a gene therapy for adults with severe hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets. The company sells its therapies through specialty healthcare and commercial distribution networks and continues to invest in treatments for rare diseases. Alexander Hardy has served as BioMarin’s president and chief executive officer since 2023.View BioMarin Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
